6vou | pdb_00006vou

Aminoglycoside N-2'-Acetyltransferase-Ia [AAC(2')-Ia] in complex with acetylated-plazomicin and CoA

spinqualitylabelsall models 6vou, resolution 1.95Å Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image   Print3D Structural highlights 6vou is a 2 chain structure with sequence from "proteus_stuartii"_buttiaux_et_al._1954 "proteus stuartii" buttiaux et al. 1954. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance. Ligands: COA, MPD, PZC, TCE Related: 6vr3, 6vr2, 6vta Gene: aac ("Proteus stuartii" Buttiaux et al. 1954) Activity: Gentamicin 2'-N-acetyltransferase, with EC number 2.3.1.59 Resources: FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT Publication Abstract from PubMed The approval of plazomicin broadened the clinical library of aminoglycosides available for use against emerging bacterial pathogens. Contrarily to other aminoglycosides, resistance to plazomicin is limited; still, instances of resistance have been reported in clinical settings. Here, we present structural insights into the mechanism of plazomicin action and the mechanisms of clinical resistance. The structural data reveal that plazomicin exclusively binds to the 16S ribosomal A site, where it likely interferes with the fidelity of mRNA translation. The unique extensions to the core aminoglycoside scaffold incorporated into the structure of plazomicin do not interfere with ribosome binding, which is analogously seen in the binding of this antibiotic to the AAC(2')-Ia resistance enzyme. The data provides a structural rationale for resistance conferred by drug acetylation and ribosome methylation, i.e., the two mechanisms of resistance observed clinically. Finally, the crystal structures of plazomicin in complex with both its target and the clinically relevant resistance factor provide a roadmap for next-generation drug development that aims to ameliorate the impact of antibiotic resistance. Structural basis for plazomicin antibiotic action and resistance.,Golkar T, Bassenden AV, Maiti K, Arya DP, Schmeing TM, Berghuis AM Commun Biol. 2021 Jun 11;4(1):729. doi: 10.1038/s42003-021-02261-4. PMID:34117352 From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Proteopedia Page Contributors and Editors (what is this?)

OCA